Orathecin

Treatment for Pancreatic Cancer

SuperGen Announces 90 Day Extension of FDA Review Date for Orathecin New Drug Application

DUBLIN, Calif., November 29, 2004 -- SuperGen, Inc. (NASDAQ:SUPG) today announced that it received notification from the U.S. Food & Drug Administration (FDA) that the Agency extended the Pharmaceutical Drug User Fee Act (PDUFA) date for completing its review of the Orathecin (rubitecan) capsules New Drug Application (NDA) to February 26, 2005. Orathecin is SuperGen's investigational drug for the treatment of pancreatic cancer patients who have failed at least one prior chemotherapy regimen.

SuperGen submitted additional data from the Company's trial of Orathecin for use as a first-line pancreatic cancer treatment that had been requested by the FDA. The Company also included several new sets of data analysis to further evaluate Orathecin in second and third line patients. Submission of this additional data was classified as a major amendment by the FDA, which allowed the Agency to extend its review by three months.

The first-line Phase III pancreatic cancer study enrolled 996 patients who were randomized to receive either Orathecin or gemcitabine. While the trial failed to reach its endpoint of improving survival over gemcitabine, the chemo-naive pancreatic cancer patients that were the subjects of this study fall outside of the proposed use of Orathecin as a second and/or third line therapy in the current NDA SuperGen submitted on January 27, 2004. The treatment of chemo-naive pancreatic cancer patients with Orathecin will be further explored in a proposed, post-marketing, confirmatory study of gemcitabine with or without Orathecin. The completed single agent, chemo- naive study, along with other completed Orathecin trial data, will be presented in a future scientific forum.

"The additional clinical data submitted to the FDA provides additional support for the Orathecin NDA," stated Dr. James Manuso, Chairman, President and Chief Executive Officer of SuperGen. "We wanted the Agency to have access to the most complete body of clinical data in order to clearly understand the utility of Orathecin."

About Orathecin
Orathecin (rubitecan) Capsules, an orally active camptothecin, is a topoisomerase I inhibitor that was developed for the treatment of pancreatic cancer.

Orathecin has Orphan Drug status in both the US and EU. The Orathecin European filing or Marketing Authorization Application contains data from a Phase III clinical program believed to be the largest program in pancreatic cancer ever initiated worldwide, with more than 1,000 patients. Orathecin is also in clinical trials for numerous other cancers and blood disorders.

SuperGen's Orathecin NDA was submitted to the FDA on January 26, 2004. It was accepted for filing and assigned a PDUFA goal date of November 26, 2004. The entire NDA now includes data on the treatment of over 1,900 advanced pancreatic cancer patients.

About Pancreatic Cancer
According to American Cancer Society Cancer Facts and Figures 2004, 31,860 people will be diagnosed with pancreatic cancer this year in the United States and 31,270 people will die. Pancreatic cancer is the fourth highest cancer killer in the United States amongst both men and women. The 99 percent mortality rate for pancreatic cancer is the highest of any cancer.

About SuperGen
Based in Dublin, California, SuperGen is a pharmaceutical company dedicated to the acquisition, rapid development and commercialization of therapies for solid tumors, hematological malignancies and blood disorders. SuperGen's product portfolio includes Nipent (pentostatin for injection); Mitomycin (generic brand of Mutamycin); and SurfaceSafe cleaner.
For more information about SuperGen, please visit www.supergen.com.

Posted: November 2004

Related Articles

Orathecin (rubitecan) FDA Approval History

View comments

Hide
(web3)